Residual Disease Driven Strategy for CARCIK (CD19) in Adults/Pediatric BCP-ALL

Summary

This is a single arm, open-label, multi-center, phase II study to determine the activity and the safety of a therapeutic strategy that allows a second CARCIK-CD19 cells infusion, driven by the status of disease from one month after the first infusion, in adult and pediatric patients with r/r BCP- ALL.

Timeline

Start

2021-12-01

Primary completion

2024-12

Completion

2025-03

Drugs

Indications